ロード中...
Lutetium Lu-177 Dotatate Flare Reaction
PURPOSE: Lutetium Lu-177 dotatate is the first peptide receptor radionuclide therapy approved by the US Food and Drug Administration. Well-designed studies in Europe have shown dramatic effectiveness in improving progression-free survival in patients with gastroenteropancreatic neuroendocrine tumors...
保存先:
| 出版年: | Adv Radiat Oncol |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7811111/ https://ncbi.nlm.nih.gov/pubmed/33490736 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.adro.2020.11.008 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|